相关实验视频
Updated: Jul 14, 2025

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
94.5K
驼奶可以通过调节2型糖尿病小鼠的肠道微生物群和代谢物来缓解高血糖症
Yongjin Zhang1, Ju Wang1, Wupeng Ge1
1College of Food Science and Engineering, Northwest A&F University, Yangling, Shaanxi 712100, China.
Food research international (Ottawa, Ont.)
|October 7, 2023
概括
牛奶 (CMPs) 通过改善肠道微生物群和代谢途径,在2型糖尿病 (T2DM) 小鼠中显示出低血糖作用. 这表明CMP可能是T2DM干预的有益营养补充剂.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 肠道微生物组研究研究
- 营养生物化学 营养生物化学
背景情况:
- 2型糖尿病 (T2DM) 是一种全球性健康问题,其特点是高血糖和胰岛素抵抗.
- 肠道微生物群失生症越来越多地被认为是T2DM病原发生的一个因素.
- 驼乳 (CMP) 是具有潜在治疗性能的生物活性化合物.
研究的目的:
- 在T2DM的小鼠模型中研究CMPs的低血糖作用.
- 阐明涉及肠道微生物群和代谢物变化的潜在机制.
- 评估CMP对T2DM代谢参数和肠道健康的影响.
主要方法:
- 将CMP给T2DM小鼠使用.
- 评估包括血糖,胰岛素抵抗和体重在内的生理参数.
- 用于肠道微生物群分析的16S rRNA测序.
- 代谢分析,以确定关键的代谢物和途径.
- 肠道微生物群,代谢物和低血糖影响之间的相关性分析.
主要成果:
- CMP显著降低了禁食血糖,改善了胰岛素敏感性,并缓解了T2DM症状.
- CMPs逆转了肠道微生物群的失生症,改变了特定细菌种群的丰富性和Firmicutes/Bacteroidetes比率.
- 代谢分析显示了诸如潘托酸和CoA生物合成等途径的变化,其中特定的代谢物与低血糖活性有关.
- 相关性分析表明,CMPs通过调节肠道微生物群,SCFA和代谢途径,产生低血糖效应.
结论:
- CMPs在T2DM小鼠中显示出显著的低血糖效应.
- 该机制涉及肠道微生物群组成和代谢概况的调节.
- 作为T2DM管理的功能性食品或营养补充剂,CMP显示出前景.
相关概念视频
Glucagon-like Receptor Agonists
337
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
337
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Dipeptidyl Peptidase 4 Inhibitors
196
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
196
Diabetes: Management and Pharmacotherapy
292
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
292
Oral Hypoglycemic Agents: Biguanides and Glitazones
215
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
215
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K

